Floatz logo

Daunorubicin

ESCC

RenJi HospitalPhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
89/ 100

Competitive context

7 Active assets in the ESCC cohort.

Asset / SponsorPhaseRating
Serplulimab
RenJi Hospital
Phase 2CCC
Cytosin-Arabinosid
RenJi Hospital
Phase 2CCC
Surufatinib
RenJi Hospital
Phase 2CCC
Jab-8263
Jacobio Pharmaceuticals Co., Ltd.
Phase 1/2CC
asp0739
Astellas Pharma Global Development, Inc.
Phase 1/2CC
Nrm-823
Normunity AccelCo, Inc.
Phase 1CC
alx2004
ALX Oncology Inc.
Phase 1CC

Same molecule, other indications

Daunorubicin is also rated in:

acute myeloid leukemia by FAB classificationDormant
BBB
Indicative ·
78 / 100
View asset →
acute myeloid leukemia with abnormal bone marrow eosinophils inv(16)(p13q22) or t(16;16)(p13;q22)Dormant
BBB
Indicative ·
77 / 100
View asset →
acute monocytic leukemiaDormant
BBB
Indicative ·
77 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →